Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarter

Corcept Therapeutics reported second-quarter 2026 results on July 29, 2026, and provided updates across its Cushing's syndrome and oncology programs. In oncology, more than 1,300 patients have started treatment with Lifyorli since its FDA approval in March 2026, with demand accelerating each month, according to the company.¹

On the regulatory front, Corcept said it anticipates the European Medicines Agency will approve its Marketing Authorization Application for relacorilant in platinum-resistant ovarian cancer later this year.¹ Separately, the company resubmitted its New Drug Application for relacorilant in Cushing's syndrome in June, with a decision expected by December 17, 2026.¹

Several trial readouts are expected by year end. Results from the trial combining relacorilant with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer patients are expected by the end of this year.¹ Separately, the company's individual studies of relacorilant in platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers are each expected to produce results by the end of next year,¹ and a study of nenocorilant combined with nivolumab in a variety of solid tumors is also expected to yield results by the end of next year.¹

In other pipeline news, results from the Phase 2b MONARCH trial in MASH patients are expected by the end of this year,¹ and Corcept plans to begin a Phase 3 ALS trial of dazucorilant, aiming to replicate the survival benefit seen in the Phase 2 DAZALS study.¹

Cash and investments stood at $544.6 million as of June 30, 2026, up from $515.4 million at the end of the first quarter.¹ Total revenue for the quarter was $256.1 million, compared with $194.4 million a year earlier.¹